Biologics Outsourcing Global Market - Forecast to 2030
Biologics Outsourcing Global Market - Forecast to 2030
Abstract
Biologics are the therapeutic entities composed of sugars, proteins, or nucleic acids and made from natural sources such as human, animal or microorganisms. Biologics also include live attenuated microorganisms (vaccines), allergenic extracts (allergy shots), human cells and tissues (for transplantation), cell and gene therapeutics. Similar to the conventional therapeutics, these drugs help in treating several diseases but are highly specific and more efficient in their disease healing mechanisms. The biologic entities like monoclonal antibodies and recombinant proteins target specific areas during their molecular mechanism of disease curing.
Even though biologics are highly expensive when compared to the conventional small molecule drugs, these target specific therapeutics have proven to be very beneficial for patients and also ensure higher profit margins to the drug manufacturers. The escalating adoption of biologics and elevating demand for the highly efficient biotherapeutics from the value-centric patient population across the globe, increasing investments on research and developmental activities of biologics and advanced, next-generation biotherapeutics, a favorable and streamlined regulatory environment that is expediting the novel product approval process and the expansion of biosimilar market have all led to the rapid growth of the biopharmaceutical market. Due to the increasing demand for biologics drugs and increased regulatory approvals for these drugs, there is huge demand for biologics manufacture and testing at various levels of clinical studies as well as commercial supply. This fast pacing biologic industry coupled with insufficient or lack of in house biologic development and manufacturing capabilities and capacities of biopharmaceutical companies has spurred these companies to outsource the different parts of biologic development and manufacturing process to highly efficient service providing organizations. The Large Biopharma companies are coming up with strategies to cut down on their operational costs and concentrate more on their core competencies by outsourcing this piece of work to contract research organizations (CROs), contract development and manufacturing organizations (CDMOs) and contract manufacturing organizations (CMOs). These organizations bridge the gap between demand and supply and ensure the drug discovery and manufacturing process gets much faster and convenient; thus bringing the life-saving drugs to the market and the needy patients at the earliest.
The biologics outsourcing global market is expected to grow at a double digit CAGR from 2022 to 2030 to reach $106.7 billion by 2030. Major drivers for the biologics outsourcing market include increasing trend of outsourcing among the biopharma companies for gaining an economical access to advanced biologics development and manufacturing capacities and capabilities, advanced bioprocessing capabilities of bioservice providers, increasing approvals and adoption of biologics, increasing R&D spend of biopharma companies and escalating approvals and uptake of biosimilars. Factors like emergence of next generation biotherapeutics, development of personalized and orphan indication therapies and the persistently escalating prevalence of chronic, communicable and autoimmune diseases are expected to boost the market growth. However, increasing focus on in-house biologics manufacturing, huge capital investments for capacity and capability development and compliance with stringent regulatory guidelines are restraining the market.
The biologics outsourcing global market has been segmented based on the developmental phase, product, end users and geography. Among the discovery, pre-clinical, clinical and commercial phases of biologics development, Commercial Phase outsourcing commanded the highest revenue in 2022 and is expected to grow at a double digit CAGR from 2022 to 2030. Clinical outsourcing segment is expected grow early teen CAGR from 2022 to 2030. The biological outsourcing market by product type is segmented into Antibody, Proteins, Vaccines, Gene therapy, cell therapy and others. Among these, the antibody outsourcing segment accounted for the highest revenue in 2022 and is expected to grow at a high single digit CAGR from 2022 to 20230. Gene therapeutics segment is expected grow at a high double digit CAGR from 2022 to 2030. Based on end-users, biologics outsourcing global market is segmented into Therapeutics, Diagnostics and Research. Among these, Therapeutics accounted for the highest revenue in 2022 and is expected to grow at a double digit CAGR from 2022 to 2030. Based on geography, biologics outsourcing global market is segmented into North America, Europe, Asia-Pacific and RoW. North America dominated the biologics outsourcing market with the highest revenue in 2022 and is expected to grow at high single digit CAGR 2022 to 2030. Whereas, Asia Pacific region is expected to be grow at an early teen CAGR from 2022 to 2030.
The report specifically emphasizes on the rapidly evolving and high growth potential biologics contract manufacturing services market and cell line development services market. The biologics contract manufacturing global market is expected to grow at double digit CAGR from 2022 to 2030. The contract biomanufacturing global market is driven by the increasing trend of outsourcing among the biopharmaceutical companies, availability of advanced bioprocessing capabilities among the contract bioservice providers, expansion of manufacturing facilities, and the escalating approval and adoption of biologics and the cost effective biosimilars among the value centric global patient pool leading to huge volume demand for biologics. Emergence of advanced biotherapeutics, increasing R&D investments by the biopharma companies, development of precision and orphan indication therapies and the persistently increasing prevalence of chronic, communicable and autoimmune diseases are also boosting contract biomanufacturing market growth.
The biologics contract biomanufacturing services global market is classified based on product, developmental phase, process, end users and geography. Based on the product, the biologics CMO global market divided into Drug substance manufacturing and Drug product manufacturing. Among these, drug substance manufacturing accounted for the highest revenue in 2022 and is expected to grow at a double digit CAGR from 2022 to 2030. The Drug Product manufacturing is expected to grow at an early teen CAGR from 2022 to 2030. Based on the developmental phase, the contract Biomanufacturing global market has been segmented as clinical phase contract biomanufacturing and commercial phase contract biomanufacturing. Among these phases, the commercial phase contract biomanufacturing accounted for the highest revenue in 2022 and is expected to grow at a double digit CAGR from 2022 to 2030. Clinical segment is expected to grow at an early teen CAGR from 2022 to 2030. Based on the process of contract biomanufacturing, the global market has been grouped into mammalian contract biomanufacturing, microbial contract biomanufacturing and other contract biomanufacturing processes (plant or insect cell based). Among these, mammalian cell culture CMO market is accounted for the highest revenue in 2022 and is expected to grow at an early teen CAGR from 2022 to 2030.
The contract biomanufacturing services global market, based on end-users has been segmented into contract biomanufacturing for diagnostics, research reagents and therapeutics. Among these, contract biomanufacturing of therapeutics accounted for the highest revenue in 2022 and is expected to grow at an early teen CAGR from 2022 to 2030. Research segment is expected to grow at an early teen CAGR from 2022 to 2030. The vectors are basic important components in the development of biological modalities such as gene therapy, cell therapy, vaccines and also in the development of recombinant cell lines CHO and others for the production of biologics such as monoclonal antibodies, recombinant proteins and others. The Viral Vector & Plasmid DNA Contract Manufacturing global market is estimated to be $XX million in 2022 and is expected to grow at early teen CAGR from 2022 to 2030. Based on vector type, Viral Vector & Plasmid DNA Contract Manufacturing global market is divided into viral vector and plasmid DNA manufacturing. Among these, Plasmid DNA Contract Manufacturing segment is accounted for the highest revenue in 2022 and is expected to grow at a mid single digit CAGR from 2022 to 2030.
Viral vector Contract Manufacturing is expected to grow at a high teen CAGR from 2022 to 2030. Based on modalities, Viral Vector and Plasmid DNA contract manufacturing global market is segmented into Vaccines, Cell & Gene Therapies and Others. Among these, Vaccines segment is accounted for the highest revenue in 2022 and is expected to grow at a high single digit CAGR from 2022 to 2030. Cell & Gene Therapies is expected to grow at a high double digit CAGR from 2022 to 2030. Based on the facility type, it can be categorized into Stainless steel and Single-use. Stainless steel CMO global manufacturing capacity is estimated to be XX million L in 2022 and is expected to grow at a high single digit CAGR from 2022 to 2030. Single-Use CMO global manufacturing capacity is expected to grow at a high double digit CAGR from 2022 to 2030. The contract biomanufacturing services global market based on geography is segmented into North America, Europe, Asia-Pacific and the Rest of the world (ROW). North America contributed highest revenue in 2022 and is growing at a high single digit CAGR from 2022 to 2030. Asia Pacific region is expected to grow at a early teen CAGR from 2022 to 2030.
The cell line development service market is expected to grow at a double digit CAGR from 2022 to 2030 to reach $2,093.2 million by 2030. Increasing demand for monoclonal antibodies, recombinant proteins and vaccines, growing incidence rate of oncology, autoimmune disorders, infectious diseases & genetic disorders and growth in research activities related to the diseases and also recombinant cell lines for the production recombinant biopharmaceutical proteins are driving the market. Technological advancements in cell line engineering (gene editing tools) & cell line development technologies, screening technologies and process development are giving immense growth opportunities for the market. However, complexities in the development of stable cell lines and high risk of contamination due to complex purification methods are restraining the market. Furthermore, stringent and complex regulations and the high cost and technical requirement to adhere to accreditations such as GMP are posing threat to the industry.
Cell line development service global market is classified based on the expression system, cell line type, application and geography. Based on expression system, cell line development service global market is segmented into microbial, mammalian and others. Among these, mammalian expression system is accounted for the highest revenue of in 2022 and is expected to grow at a double digit CAGR from 2022 to 2030. Based on the cell line type, global cell line development service market is segmented into CHO, Mouse Myeloma (NS0; Sp2/0), Human Embryonic Kidney (HEK), Baby Hamster Kidney (BHK), Hybridoma, Human Embryonic Retina (PER.C6) and others. Among these, CHO cell line accounted for the highest revenue in 2022 and is expected to grow at an early teen CAGR from 2022 to 2030. Based on application, cell line development service global market is segmented into research, bio production and diagnostics. Among these, bioproduction segment accounted for the highest revenue in 2022 and is expected to grow at a double digit CAGR from 2022 to 2030. Based on the geography, cell line development service global market is segmented into North America, Europe, Asia-Pacific and Rest of the world. North America commanded the highest revenue in 2022. The market is expected to grow at a high single digit CAGR from 2022 to 2030. Asia Pacific is expected to grow at an early teen CAGR from 2022 to 2030.
The top players in biologics outsourcing global market are Lonza (Switzerland), Catalent (U.S.), SamSung Biologics (South Korea), WuXi Biologics (China), Thermo Fisher (Patheon N.V.+Brammer Bio) (U.S.), FUJIFILM Holdings Corporation (FujiFilm Diosynth) (Japan), Merck KGaA (Germany), Boehringer Ingelheim (Germany), Laboratory Corporation of America Holdings (U.S.), Charles River Laboratories (U.S.), JSR corporation (U.S.), WuXi Apptech (China), Genscript Biotech Corporation (China), Emergent Biosciences (U.S.), Asahi Glass Company (AGC Biologics) (Japan) and others.
Content
Table of Contents
1 BIOLOGICS OUTSOURCING GLOBAL MARKET 22
1.1 EXCEUTIVE SUMMARY 22
1.2 LANDSCAPE OF BIOLOGICS MARKET 36
1.3 RISE OF BIOSIMILARS 38
1.4 BIOSIMILARS GLOBAL MARKET, BY REGION 44
1.5 BIOLOGICS GLOBAL MARKET 60
1.6 TOP DESTINATION FOR BIOLOGICS OUTSOURCING 62
1.6.1 CHINA BIOLOGICS OUTSOURCING MARKET 62
1.6.2 INDIA BIOLOGICS OUTSOURCING MARKET 65
1.6.3 CHINA VS INDIA - BIOLOGICS MARKET 67
1.6.4 REGULATIONS AND GOVERNMENT INITIATIVES 71
1.6.5 CAPABILITIES AND TECHNOLOGIES 76
2 MARKET ANALYSIS 80
2.1 INTRODUCTION 80
2.2 FACTORS INFLUENCING MARKET 81
2.2.1 DRIVERS AND OPPORTUNITIES 82
2.2.1.1 Increasing trend of outsourcing 82
2.2.1.2 Advanced bioprocessing capabilities of bioservice providers 84
2.2.1.3 Emergence of next generation biologics 86
2.2.1.4 Escalating approvals and uptake of biosimilars 88
2.2.1.5 Increasing approvals and adoption of biologics 91
2.2.1.6 Increasing R&D expenditures 92
2.2.1.7 Increasing prevalence of chronic, communicable and autoimmune diseases 93
2.2.1.8 Development of personalized and orphan indication therapies 94
2.2.2 RESTRAINTS AND THREATS 95
2.2.2.1 Increasing focus on in-house biologics manufacturing 95
2.2.2.2 Huge capital investments for capacity and capability development 95
2.2.2.3 Compliance with stringent regulatory guidelines 97
2.2.2.4 Concerns about IP protection 99
2.2.2.5 Competition and trend of outsourcing of low volume biologics 99
3 BIOLOGICS OUTSOURCING GLOBAL MARKET, MARKET ANALYSIS 101
3.1 INTRODUCTION 101
3.2 BIOLOGICS OUTSOURCING GLOBAL MARKET BASED ON PHASE 105
3.2.1 DISCOVERY AND PRE-CLINICAL DEVELOPMENT PROCESS 106
3.3 BIOLOGICS OUTSOURCING GLOBAL MARKET, BASED ON PRODUCT TYPE 116
3.3.1 ANTIBODY 123
3.3.1.1 Monoclonal antibody 125
3.3.1.2 Bispecific antibody 129
3.3.1.3 Antibody drug conjugates 131
3.3.1.4 Others (polyclonal antibody, antibody fragments) 133
3.3.2 RECOMBINANT PROTEIN 135
3.3.3 VACCINES 142
3.3.4 GENE THERAPY 146
3.3.5 CELL THERAPY 148
3.3.6 OTHERS 151
3.4 BIOLOGICS OUTSOURCING GLOBAL MARKET, BASED ON ENDUSERS 153
3.4.1 THERAPEUTICS 156
3.4.2 DIAGNOSTICS 157
3.4.3 RESEARCH 158
3.5 BIOANALYTICAL TESTING SERVICES 159
3.6 MARKET SHARE ANALYSIS 162
3.7 COMPANY DEVELOPMENTS 168
3.7.1 AGREEMENT, COLLABORATIONS AND PARTNERSHIPS 169
3.7.2 EXPANSION 206
3.7.3 ACQUISITIONS 228
3.7.4 FACILITY APPROVAL 238
3.7.5 NEW PRODUCT, TECHNOLGY AND SERVICE LAUNCH 241
3.7.6 OTHERS 245
3.8 SERVICE COST ANALYSIS 248
3.8.1 ANTIBODY PRODUCTION SERVICE COSTS 248
3.8.2 CUSTOM MONOCLONAL ANTIBODY PRODUCTION SERVICE COSTS 252
3.8.3 CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE COSTS 254
3.8.4 PROTEIN PRODUCTION SERVICE COSTS 255
3.8.5 ADDITIONAL ANTIBODY AND PROTEIN SERVICES 258
3.8.6 GENE EDITTING SERVICES 260
3.8.7 CAR-T/NK PLATFORM SERVICES 260
4 BIOLOGICS OUTSOURCING GLOBAL MARKET - BIOMANUFACTURING 265
4.1 INTRODUCTION 265
4.2 MARKET DYNAMICS 269
4.3 BIOLOGICS CMO GLOBAL MARKET BASED ON PRODUCT 270
4.3.1 DRUG SUBSTANCE MANUFACTURING 271
4.3.2 DRUG PRODUCT MANUFACTURING 272
4.4 IN HOUSE VS CMO CAPACITY 272
4.4.1 IN-HOUSE 273
4.4.2 CMO 274
4.5 GLOBAL BIOMANUFACTURING CAPACITY 276
4.6 BIOLOGICS CONTRACT MANUFACTURING ORGANIZATIONS,
BASED ON PHASE 280
4.6.1 CLINICAL 281
4.6.2 COMMERCIAL 282
4.7 CONTRACT BIOMANUFACTURING, BASED ON PROCESS 283
4.7.1 BIOMANUFACTURING BY MAMMALIAN CELL CULTURE 285
4.7.2 MAMMALIAN CELL CULTURE BIOMANUFACTURING V/S MICROBIAL AND OTHER CELL CULTURES 290
4.7.3 BIOMANUFACTURING BY MICROBIAL CELL CULTURE 294
4.7.4 MICROBIAL CELL CULTURE CMO BIOMANUFACTURING CAPACITY 297
4.7.5 BIOMANUFACTURING BY OTHER CELL CULTURE 298
4.8 CONTRACT BIOMANUFACTURING GLOBAL MARKET, BASED ON END USERS 300
4.8.1 CONTRACT BIOMANUFACTURING OF DIAGNOSTICS 302
4.8.2 CONTRACT BIOMANUFACTURING OF RESEARCH REAGENTS 303
4.8.3 CONTRACT BIOMANUFACTURING OF THERAPEUTICS 304
4.8.3.1 BIOMANUFACTURING OF ANTIBODIES 305
4.8.3.2 BIOMANUFACTURING OF RECOMBINANT PROTEINS 310
4.8.3.3 BIOMANUFACTURING OF VACCINES 311
4.8.3.4 GENE THERAPY, CELL THERAPY AND OTHER BIOLOGICS CONTRACT BIOMANUFACTURING 313
4.9 BIOMANUFACTURING OUTSOURCING GLOBAL MARKET, BASED ON REGION 315
4.10 VIRAL VECTOR & PLASMID DNA CONTRACT MANUFACTURING MARKET BASED ON VECTOR TYPE 321
4.10.1 VIRAL VECTOR CONTRACT MANUFACTRUING 323
4.10.2 PLASMID DNA CONTRACT MANUFACTRUING 326
4.11 VIRAL VECTOR & PLASMID DNA CONTRACT MANUFACTURING MARKET, BASED ON MODALITY 330
4.11.1 VACCINES 333
4.11.2 CELL AND GENE THERAPIES 334
4.11.3 OTHERS 336
4.12 CONTRACT BIOMANUFACTURING CAPACITY PENETRATION 337
4.12.1 CAPACITY COMPARISION 340
4.13 STAINLESS STEEL VS SINGLE-USE FACILITIES 342
4.13.1 STAINLESS STEEL FACILITY 345
4.13.2 SINGLE-USE FACILITY 348
4.13.3 COST OF GOODS COMPARSION BETWEEN STAINLESS STEEL AND SINGLE-USE FACILITIES 357
4.14 COMPETATIVE LANDSCAPE 358
4.14.1 CONTRACT MANUFACTURING GLOBAL MARKET SHARE, BY LEADING PLAYERS 358
4.14.2 COMPANY DEVELOPMENTS 362
4.14.2.1 EXPANSION 363
4.14.2.2 COLLABORATION AND PARTNERSHIP 383
4.14.2.3 AGREEMENT 401
4.14.2.4 ACQUISITION 411
4.14.2.5 FACILITY APPROVALS 419
4.14.2.6 NEW PRODUCT, TECHNOLOGY AND SERVICE LAUNCH 422
4.14.2.7 OTHER DEVELOPMENTS 424
5 BIOLOGICS OUTSOURCING GLOBAL MARKET - CELL LINE DEVELOPMENT 429
5.1 INTRODUCTION 429
5.1.1 MARKET DYNAMICS 431
5.2 CELL LINE DEVELOPMENT 433
5.2.1 CELL LINE CONSTRUCTION 433
5.2.2 HOST CELL LINE ENGINEERING EXPRESSION SYSTEM 434
5.2.3 EXPRESSION VECTOR AND HOST CELL LINE ENGINEERING 435
5.2.4 TRANSIENT GENE EXPRESSION 437
5.2.5 STABLE CELL LINE DEVELOPMENT 438
5.2.6 SCREENING 439
5.2.7 UPSTREAM PROCESS DEVELOPMENT 441
5.3 HOST CELL LINES 442
5.4 CELL LINE DEVELOPMENT SERVICES MARKET, BASED ON EXPRESSION SYSTEM 449
5.4.1 MAMMALIAN EXPRESSION SYSTEMS 453
5.4.2 MICROBIAL EXPRESSION SYSTEMS 456
5.4.3 OTHERS (INSECT AND PLANT CELL) 457
5.5 CELL LINE DEVELOPMENT SERVICES, BASED ON CELL LINE TYPE 459
5.5.1 CHO 462
5.5.2 MURINE/MOUSE MYELOMA (NS0, SP2/0) 465
5.5.3 BABY HAMSTER KIDNEY (BHK) CELLS 466
5.5.4 HUMAN EMBRYONIC KIDNEY (HEK) CELLS 466
5.5.5 HUMAN EMBRYONIC RETINAL CELLS (PER.C6) 468
5.5.6 HYBRIDOMA 468
5.5.7 OTHERS (E.COLI, YEAST, INSECT CELL, HT-1080, HELA CELL LINE, CAP, HKB-11, HUH-7) 469
5.6 CELL LINE DEVELOPMENT SERVICES, BASED ON APPLICATIONS 474
5.6.1 RESEARCH 476
5.6.2 BIOPRODUCTION 480
5.6.3 DIAGNOSTICS 482
5.7 CELL BANKING SERVICES 497
5.8 CELL LINE CHARACTERIZATION SERVICES 499
5.9 MARKET SHARE ANALYSIS 502
5.10 KEY DEVELOPMENTS 507
5.10.1 AGREEMENT, COLLABORATION AND PARTNERSHIP 508
5.10.2 NEW TECHNOLOGY, PRODUCT AND SERVICE LAUNCH 511
5.10.3 OTHER DEVELOPMENTS 512
6 COMPANY PROFILES 516
6.1 ABBVIE INC. 516
6.1.1 OVERVIEW 516
6.1.2 FINANCIALS 518
6.1.3 SERVICE PORTFOLIO 520
6.1.4 KEY DEVELOPMENTS 522
6.1.5 SWOT ANALYSIS 522
6.2 AGC INC. 523
6.2.1 OVERVIEW 523
6.2.2 FINANCIALS 525
6.2.3 SERVICE PORTFOLIO 528
6.2.4 KEY DEVELOPMENTS 529
6.2.5 SWOT ANALYSIS 535
6.3 AVID BIOSERVICES, INC. 536
6.3.1 OVERVIEW 536
6.3.2 FINANCIALS 537
6.3.3 SERVICE PORTFOLIO 537
6.3.4 KEY DEVELOPMENTS 541
6.3.5 SWOT ANALYSIS 543
6.4 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 544
6.4.1 OVERVIEW 544
6.4.2 FINANCIALS 546
6.4.3 SERVICE PORTFOLIO 548
6.4.4 KEY DEVELOPMENTS 549
6.4.5 SWOT ANALYSIS 549
6.5 CATALENT INC. 550
6.5.1 OVERVIEW 550
6.5.2 FINANCIALS 552
6.5.3 SERVICE PORTFOLIO 554
6.5.4 KEY DEVELOPMENTS 555
6.5.5 SWOT ANALYSIS 563
6.6 CHARLES RIVER LABORATORIES 564
6.6.1 OVERVIEW 564
6.6.2 FINANCIALS 566
6.6.3 SERVICE PORTFOLIO 568
6.6.4 KEY DEVELOPMENTS 569
6.6.5 SWOT ANALYSIS 572
6.7 CURIA 573
6.7.1 OVERVIEW 573
6.7.2 FINANCIALS 573
6.7.3 SERVICE PORTFOLIO 573
6.7.4 KEY DEVELOPMENTS 576
6.7.5 SWOT ANALYSIS 578
6.8 EMERGENT BIOSOLUTIONS INC. 579
6.8.1 OVERVIEW 579
6.8.2 FINANCIALS 580
6.8.3 SERVICE PORTFOLIO 580
6.8.4 KEY DEVELOPMENTS 582
6.8.5 SWOT ANALYSIS 583
6.9 EUROFINS SCIENTIFIC S.E. 584
6.9.1 OVERVIEW 584
6.9.2 FINANCIALS 586
6.9.3 SERVICE PORTFOLIO 587
6.9.4 KEY DEVELOPMENTS 588
6.9.5 SWOT ANALYSIS 589
6.10 FUJIFILM HOLDINGS CORPORATION (FUJIFILM DIOSYNTH BIOTECHNOL0GIES) 590
6.10.1 OVERVIEW 590
6.10.2 FINANCIALS 592
6.10.3 SERVICE PORTFOLIO 594
6.10.4 KEY DEVELOPMENTS 594
6.10.5 SWOT ANALYSIS 598
6.11 GENSCRIPT BIOTECH CORPORATION 599
6.11.1 OVERVIEW 599
6.11.2 FINANCIALS 601
6.11.3 SERVICE PORTFOLIO 603
6.11.4 KEY DEVELOPMENTS 604
6.11.5 SWOT ANALYSIS 608
6.12 JSR CORPORATION 609
6.12.1 OVERVIEW 609
6.12.2 FINANCIALS 611
6.12.3 SERVICE PORTFOLIO 612
6.12.4 KEY DEVELOPMENTS 614
6.12.5 SWOT ANALYSIS 616
6.13 LABORATORY CORP OF AMERICA HOLDINGS 617
6.13.1 OVERVIEW 617
6.13.2 FINANCIALS 619
6.13.3 SERVICE PORTFOLIO 620
6.13.4 KEY DEVELOPMENTS 621
6.13.5 SWOT ANALYSIS 622
6.14 LONZA GROUP LTD. 623
6.14.1 OVERVIEW 623
6.14.2 FINANCIALS 625
6.14.3 SERVICE PORTFOLIO 627
6.14.4 KEY DEVELOPMENTS 629
6.14.5 SWOT ANALYSIS 638
6.15 MERCK KGA 639
6.15.1 OVERVIEW 639
6.15.2 FINANCIALS 641
6.15.3 PRODUCT PORTFOLIO 643
6.15.4 KEY DEVELOPMENTS 644
6.15.5 SWOT ANALYSIS 646
6.16 NATIONAL RESILIENCE, INC. 647
6.16.1 OVERVIEW 647
6.16.2 FINANCIALS 647
6.16.3 SERVICE PORTFOLIO 647
6.16.4 KEY DEVELOPMENTS 649
6.16.5 SWOT ANALYSIS 651
6.17 RENTSCHLER BIOPHARMA SE 652
6.17.1 OVERVIEW 652
6.17.2 FINANCIALS 652
6.17.3 SERVICE PORTFOLIO 653
6.17.4 KEY DEVELOPMENTS 654
6.17.5 SWOT ANALYSIS 657
6.18 SAMSUNG BIOLOGICS CO. LTD. 658
6.18.1 OVERVIEW 658
6.18.2 FINANCIALS 659
6.18.3 SERVICE PORTFOLIO 660
6.18.4 KEY DEVELOPMENTS 661
6.18.5 SWOT ANALYSIS 666
6.19 THERMO FISHER SCIENTIFIC INC. 667
6.19.1 OVERVIEW 667
6.19.2 FINANCIALS 669
6.19.3 SERVICE PORTFOLIO 671
6.19.4 KEY DEVELOPMENTS 672
6.19.5 SWOT ANALYSIS 676
6.20 WUXI APPTEC CO., LTD. 677
6.20.1 OVERVIEW 677
6.20.2 FINANCIALS 679
6.20.3 SERVICE PORTFOLIO 681
6.20.4 KEY DEVELOPMENTS 682
6.20.5 SWOT ANALYSIS 685
6.21 WUXI BIOLOGICS (CAYMAN) INC. 686
6.21.1 OVERVIEW 686
6.21.2 FINANCIALS 688
6.21.3 SERVICE PORTFOLIO 690
6.21.4 KEY DEVELOPMENTS 697
6.21.5 SWOT ANALYSIS 705
Even though biologics are highly expensive when compared to the conventional small molecule drugs, these target specific therapeutics have proven to be very beneficial for patients and also ensure higher profit margins to the drug manufacturers. The escalating adoption of biologics and elevating demand for the highly efficient biotherapeutics from the value-centric patient population across the globe, increasing investments on research and developmental activities of biologics and advanced, next-generation biotherapeutics, a favorable and streamlined regulatory environment that is expediting the novel product approval process and the expansion of biosimilar market have all led to the rapid growth of the biopharmaceutical market. Due to the increasing demand for biologics drugs and increased regulatory approvals for these drugs, there is huge demand for biologics manufacture and testing at various levels of clinical studies as well as commercial supply. This fast pacing biologic industry coupled with insufficient or lack of in house biologic development and manufacturing capabilities and capacities of biopharmaceutical companies has spurred these companies to outsource the different parts of biologic development and manufacturing process to highly efficient service providing organizations. The Large Biopharma companies are coming up with strategies to cut down on their operational costs and concentrate more on their core competencies by outsourcing this piece of work to contract research organizations (CROs), contract development and manufacturing organizations (CDMOs) and contract manufacturing organizations (CMOs). These organizations bridge the gap between demand and supply and ensure the drug discovery and manufacturing process gets much faster and convenient; thus bringing the life-saving drugs to the market and the needy patients at the earliest.
The biologics outsourcing global market is expected to grow at a double digit CAGR from 2022 to 2030 to reach $106.7 billion by 2030. Major drivers for the biologics outsourcing market include increasing trend of outsourcing among the biopharma companies for gaining an economical access to advanced biologics development and manufacturing capacities and capabilities, advanced bioprocessing capabilities of bioservice providers, increasing approvals and adoption of biologics, increasing R&D spend of biopharma companies and escalating approvals and uptake of biosimilars. Factors like emergence of next generation biotherapeutics, development of personalized and orphan indication therapies and the persistently escalating prevalence of chronic, communicable and autoimmune diseases are expected to boost the market growth. However, increasing focus on in-house biologics manufacturing, huge capital investments for capacity and capability development and compliance with stringent regulatory guidelines are restraining the market.
The biologics outsourcing global market has been segmented based on the developmental phase, product, end users and geography. Among the discovery, pre-clinical, clinical and commercial phases of biologics development, Commercial Phase outsourcing commanded the highest revenue in 2022 and is expected to grow at a double digit CAGR from 2022 to 2030. Clinical outsourcing segment is expected grow early teen CAGR from 2022 to 2030. The biological outsourcing market by product type is segmented into Antibody, Proteins, Vaccines, Gene therapy, cell therapy and others. Among these, the antibody outsourcing segment accounted for the highest revenue in 2022 and is expected to grow at a high single digit CAGR from 2022 to 20230. Gene therapeutics segment is expected grow at a high double digit CAGR from 2022 to 2030. Based on end-users, biologics outsourcing global market is segmented into Therapeutics, Diagnostics and Research. Among these, Therapeutics accounted for the highest revenue in 2022 and is expected to grow at a double digit CAGR from 2022 to 2030. Based on geography, biologics outsourcing global market is segmented into North America, Europe, Asia-Pacific and RoW. North America dominated the biologics outsourcing market with the highest revenue in 2022 and is expected to grow at high single digit CAGR 2022 to 2030. Whereas, Asia Pacific region is expected to be grow at an early teen CAGR from 2022 to 2030.
The report specifically emphasizes on the rapidly evolving and high growth potential biologics contract manufacturing services market and cell line development services market. The biologics contract manufacturing global market is expected to grow at double digit CAGR from 2022 to 2030. The contract biomanufacturing global market is driven by the increasing trend of outsourcing among the biopharmaceutical companies, availability of advanced bioprocessing capabilities among the contract bioservice providers, expansion of manufacturing facilities, and the escalating approval and adoption of biologics and the cost effective biosimilars among the value centric global patient pool leading to huge volume demand for biologics. Emergence of advanced biotherapeutics, increasing R&D investments by the biopharma companies, development of precision and orphan indication therapies and the persistently increasing prevalence of chronic, communicable and autoimmune diseases are also boosting contract biomanufacturing market growth.
The biologics contract biomanufacturing services global market is classified based on product, developmental phase, process, end users and geography. Based on the product, the biologics CMO global market divided into Drug substance manufacturing and Drug product manufacturing. Among these, drug substance manufacturing accounted for the highest revenue in 2022 and is expected to grow at a double digit CAGR from 2022 to 2030. The Drug Product manufacturing is expected to grow at an early teen CAGR from 2022 to 2030. Based on the developmental phase, the contract Biomanufacturing global market has been segmented as clinical phase contract biomanufacturing and commercial phase contract biomanufacturing. Among these phases, the commercial phase contract biomanufacturing accounted for the highest revenue in 2022 and is expected to grow at a double digit CAGR from 2022 to 2030. Clinical segment is expected to grow at an early teen CAGR from 2022 to 2030. Based on the process of contract biomanufacturing, the global market has been grouped into mammalian contract biomanufacturing, microbial contract biomanufacturing and other contract biomanufacturing processes (plant or insect cell based). Among these, mammalian cell culture CMO market is accounted for the highest revenue in 2022 and is expected to grow at an early teen CAGR from 2022 to 2030.
The contract biomanufacturing services global market, based on end-users has been segmented into contract biomanufacturing for diagnostics, research reagents and therapeutics. Among these, contract biomanufacturing of therapeutics accounted for the highest revenue in 2022 and is expected to grow at an early teen CAGR from 2022 to 2030. Research segment is expected to grow at an early teen CAGR from 2022 to 2030. The vectors are basic important components in the development of biological modalities such as gene therapy, cell therapy, vaccines and also in the development of recombinant cell lines CHO and others for the production of biologics such as monoclonal antibodies, recombinant proteins and others. The Viral Vector & Plasmid DNA Contract Manufacturing global market is estimated to be $XX million in 2022 and is expected to grow at early teen CAGR from 2022 to 2030. Based on vector type, Viral Vector & Plasmid DNA Contract Manufacturing global market is divided into viral vector and plasmid DNA manufacturing. Among these, Plasmid DNA Contract Manufacturing segment is accounted for the highest revenue in 2022 and is expected to grow at a mid single digit CAGR from 2022 to 2030.
Viral vector Contract Manufacturing is expected to grow at a high teen CAGR from 2022 to 2030. Based on modalities, Viral Vector and Plasmid DNA contract manufacturing global market is segmented into Vaccines, Cell & Gene Therapies and Others. Among these, Vaccines segment is accounted for the highest revenue in 2022 and is expected to grow at a high single digit CAGR from 2022 to 2030. Cell & Gene Therapies is expected to grow at a high double digit CAGR from 2022 to 2030. Based on the facility type, it can be categorized into Stainless steel and Single-use. Stainless steel CMO global manufacturing capacity is estimated to be XX million L in 2022 and is expected to grow at a high single digit CAGR from 2022 to 2030. Single-Use CMO global manufacturing capacity is expected to grow at a high double digit CAGR from 2022 to 2030. The contract biomanufacturing services global market based on geography is segmented into North America, Europe, Asia-Pacific and the Rest of the world (ROW). North America contributed highest revenue in 2022 and is growing at a high single digit CAGR from 2022 to 2030. Asia Pacific region is expected to grow at a early teen CAGR from 2022 to 2030.
The cell line development service market is expected to grow at a double digit CAGR from 2022 to 2030 to reach $2,093.2 million by 2030. Increasing demand for monoclonal antibodies, recombinant proteins and vaccines, growing incidence rate of oncology, autoimmune disorders, infectious diseases & genetic disorders and growth in research activities related to the diseases and also recombinant cell lines for the production recombinant biopharmaceutical proteins are driving the market. Technological advancements in cell line engineering (gene editing tools) & cell line development technologies, screening technologies and process development are giving immense growth opportunities for the market. However, complexities in the development of stable cell lines and high risk of contamination due to complex purification methods are restraining the market. Furthermore, stringent and complex regulations and the high cost and technical requirement to adhere to accreditations such as GMP are posing threat to the industry.
Cell line development service global market is classified based on the expression system, cell line type, application and geography. Based on expression system, cell line development service global market is segmented into microbial, mammalian and others. Among these, mammalian expression system is accounted for the highest revenue of in 2022 and is expected to grow at a double digit CAGR from 2022 to 2030. Based on the cell line type, global cell line development service market is segmented into CHO, Mouse Myeloma (NS0; Sp2/0), Human Embryonic Kidney (HEK), Baby Hamster Kidney (BHK), Hybridoma, Human Embryonic Retina (PER.C6) and others. Among these, CHO cell line accounted for the highest revenue in 2022 and is expected to grow at an early teen CAGR from 2022 to 2030. Based on application, cell line development service global market is segmented into research, bio production and diagnostics. Among these, bioproduction segment accounted for the highest revenue in 2022 and is expected to grow at a double digit CAGR from 2022 to 2030. Based on the geography, cell line development service global market is segmented into North America, Europe, Asia-Pacific and Rest of the world. North America commanded the highest revenue in 2022. The market is expected to grow at a high single digit CAGR from 2022 to 2030. Asia Pacific is expected to grow at an early teen CAGR from 2022 to 2030.
The top players in biologics outsourcing global market are Lonza (Switzerland), Catalent (U.S.), SamSung Biologics (South Korea), WuXi Biologics (China), Thermo Fisher (Patheon N.V.+Brammer Bio) (U.S.), FUJIFILM Holdings Corporation (FujiFilm Diosynth) (Japan), Merck KGaA (Germany), Boehringer Ingelheim (Germany), Laboratory Corporation of America Holdings (U.S.), Charles River Laboratories (U.S.), JSR corporation (U.S.), WuXi Apptech (China), Genscript Biotech Corporation (China), Emergent Biosciences (U.S.), Asahi Glass Company (AGC Biologics) (Japan) and others.
1 BIOLOGICS OUTSOURCING GLOBAL MARKET 22
1.1 EXCEUTIVE SUMMARY 22
1.2 LANDSCAPE OF BIOLOGICS MARKET 36
1.3 RISE OF BIOSIMILARS 38
1.4 BIOSIMILARS GLOBAL MARKET, BY REGION 44
1.5 BIOLOGICS GLOBAL MARKET 60
1.6 TOP DESTINATION FOR BIOLOGICS OUTSOURCING 62
1.6.1 CHINA BIOLOGICS OUTSOURCING MARKET 62
1.6.2 INDIA BIOLOGICS OUTSOURCING MARKET 65
1.6.3 CHINA VS INDIA - BIOLOGICS MARKET 67
1.6.4 REGULATIONS AND GOVERNMENT INITIATIVES 71
1.6.5 CAPABILITIES AND TECHNOLOGIES 76
2 MARKET ANALYSIS 80
2.1 INTRODUCTION 80
2.2 FACTORS INFLUENCING MARKET 81
2.2.1 DRIVERS AND OPPORTUNITIES 82
2.2.1.1 Increasing trend of outsourcing 82
2.2.1.2 Advanced bioprocessing capabilities of bioservice providers 84
2.2.1.3 Emergence of next generation biologics 86
2.2.1.4 Escalating approvals and uptake of biosimilars 88
2.2.1.5 Increasing approvals and adoption of biologics 91
2.2.1.6 Increasing R&D expenditures 92
2.2.1.7 Increasing prevalence of chronic, communicable and autoimmune diseases 93
2.2.1.8 Development of personalized and orphan indication therapies 94
2.2.2 RESTRAINTS AND THREATS 95
2.2.2.1 Increasing focus on in-house biologics manufacturing 95
2.2.2.2 Huge capital investments for capacity and capability development 95
2.2.2.3 Compliance with stringent regulatory guidelines 97
2.2.2.4 Concerns about IP protection 99
2.2.2.5 Competition and trend of outsourcing of low volume biologics 99
3 BIOLOGICS OUTSOURCING GLOBAL MARKET, MARKET ANALYSIS 101
3.1 INTRODUCTION 101
3.2 BIOLOGICS OUTSOURCING GLOBAL MARKET BASED ON PHASE 105
3.2.1 DISCOVERY AND PRE-CLINICAL DEVELOPMENT PROCESS 106
3.3 BIOLOGICS OUTSOURCING GLOBAL MARKET, BASED ON PRODUCT TYPE 116
3.3.1 ANTIBODY 123
3.3.1.1 Monoclonal antibody 125
3.3.1.2 Bispecific antibody 129
3.3.1.3 Antibody drug conjugates 131
3.3.1.4 Others (polyclonal antibody, antibody fragments) 133
3.3.2 RECOMBINANT PROTEIN 135
3.3.3 VACCINES 142
3.3.4 GENE THERAPY 146
3.3.5 CELL THERAPY 148
3.3.6 OTHERS 151
3.4 BIOLOGICS OUTSOURCING GLOBAL MARKET, BASED ON ENDUSERS 153
3.4.1 THERAPEUTICS 156
3.4.2 DIAGNOSTICS 157
3.4.3 RESEARCH 158
3.5 BIOANALYTICAL TESTING SERVICES 159
3.6 MARKET SHARE ANALYSIS 162
3.7 COMPANY DEVELOPMENTS 168
3.7.1 AGREEMENT, COLLABORATIONS AND PARTNERSHIPS 169
3.7.2 EXPANSION 206
3.7.3 ACQUISITIONS 228
3.7.4 FACILITY APPROVAL 238
3.7.5 NEW PRODUCT, TECHNOLGY AND SERVICE LAUNCH 241
3.7.6 OTHERS 245
3.8 SERVICE COST ANALYSIS 248
3.8.1 ANTIBODY PRODUCTION SERVICE COSTS 248
3.8.2 CUSTOM MONOCLONAL ANTIBODY PRODUCTION SERVICE COSTS 252
3.8.3 CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE COSTS 254
3.8.4 PROTEIN PRODUCTION SERVICE COSTS 255
3.8.5 ADDITIONAL ANTIBODY AND PROTEIN SERVICES 258
3.8.6 GENE EDITTING SERVICES 260
3.8.7 CAR-T/NK PLATFORM SERVICES 260
4 BIOLOGICS OUTSOURCING GLOBAL MARKET - BIOMANUFACTURING 265
4.1 INTRODUCTION 265
4.2 MARKET DYNAMICS 269
4.3 BIOLOGICS CMO GLOBAL MARKET BASED ON PRODUCT 270
4.3.1 DRUG SUBSTANCE MANUFACTURING 271
4.3.2 DRUG PRODUCT MANUFACTURING 272
4.4 IN HOUSE VS CMO CAPACITY 272
4.4.1 IN-HOUSE 273
4.4.2 CMO 274
4.5 GLOBAL BIOMANUFACTURING CAPACITY 276
4.6 BIOLOGICS CONTRACT MANUFACTURING ORGANIZATIONS,
BASED ON PHASE 280
4.6.1 CLINICAL 281
4.6.2 COMMERCIAL 282
4.7 CONTRACT BIOMANUFACTURING, BASED ON PROCESS 283
4.7.1 BIOMANUFACTURING BY MAMMALIAN CELL CULTURE 285
4.7.2 MAMMALIAN CELL CULTURE BIOMANUFACTURING V/S MICROBIAL AND OTHER CELL CULTURES 290
4.7.3 BIOMANUFACTURING BY MICROBIAL CELL CULTURE 294
4.7.4 MICROBIAL CELL CULTURE CMO BIOMANUFACTURING CAPACITY 297
4.7.5 BIOMANUFACTURING BY OTHER CELL CULTURE 298
4.8 CONTRACT BIOMANUFACTURING GLOBAL MARKET, BASED ON END USERS 300
4.8.1 CONTRACT BIOMANUFACTURING OF DIAGNOSTICS 302
4.8.2 CONTRACT BIOMANUFACTURING OF RESEARCH REAGENTS 303
4.8.3 CONTRACT BIOMANUFACTURING OF THERAPEUTICS 304
4.8.3.1 BIOMANUFACTURING OF ANTIBODIES 305
4.8.3.2 BIOMANUFACTURING OF RECOMBINANT PROTEINS 310
4.8.3.3 BIOMANUFACTURING OF VACCINES 311
4.8.3.4 GENE THERAPY, CELL THERAPY AND OTHER BIOLOGICS CONTRACT BIOMANUFACTURING 313
4.9 BIOMANUFACTURING OUTSOURCING GLOBAL MARKET, BASED ON REGION 315
4.10 VIRAL VECTOR & PLASMID DNA CONTRACT MANUFACTURING MARKET BASED ON VECTOR TYPE 321
4.10.1 VIRAL VECTOR CONTRACT MANUFACTRUING 323
4.10.2 PLASMID DNA CONTRACT MANUFACTRUING 326
4.11 VIRAL VECTOR & PLASMID DNA CONTRACT MANUFACTURING MARKET, BASED ON MODALITY 330
4.11.1 VACCINES 333
4.11.2 CELL AND GENE THERAPIES 334
4.11.3 OTHERS 336
4.12 CONTRACT BIOMANUFACTURING CAPACITY PENETRATION 337
4.12.1 CAPACITY COMPARISION 340
4.13 STAINLESS STEEL VS SINGLE-USE FACILITIES 342
4.13.1 STAINLESS STEEL FACILITY 345
4.13.2 SINGLE-USE FACILITY 348
4.13.3 COST OF GOODS COMPARSION BETWEEN STAINLESS STEEL AND SINGLE-USE FACILITIES 357
4.14 COMPETATIVE LANDSCAPE 358
4.14.1 CONTRACT MANUFACTURING GLOBAL MARKET SHARE, BY LEADING PLAYERS 358
4.14.2 COMPANY DEVELOPMENTS 362
4.14.2.1 EXPANSION 363
4.14.2.2 COLLABORATION AND PARTNERSHIP 383
4.14.2.3 AGREEMENT 401
4.14.2.4 ACQUISITION 411
4.14.2.5 FACILITY APPROVALS 419
4.14.2.6 NEW PRODUCT, TECHNOLOGY AND SERVICE LAUNCH 422
4.14.2.7 OTHER DEVELOPMENTS 424
5 BIOLOGICS OUTSOURCING GLOBAL MARKET - CELL LINE DEVELOPMENT 429
5.1 INTRODUCTION 429
5.1.1 MARKET DYNAMICS 431
5.2 CELL LINE DEVELOPMENT 433
5.2.1 CELL LINE CONSTRUCTION 433
5.2.2 HOST CELL LINE ENGINEERING EXPRESSION SYSTEM 434
5.2.3 EXPRESSION VECTOR AND HOST CELL LINE ENGINEERING 435
5.2.4 TRANSIENT GENE EXPRESSION 437
5.2.5 STABLE CELL LINE DEVELOPMENT 438
5.2.6 SCREENING 439
5.2.7 UPSTREAM PROCESS DEVELOPMENT 441
5.3 HOST CELL LINES 442
5.4 CELL LINE DEVELOPMENT SERVICES MARKET, BASED ON EXPRESSION SYSTEM 449
5.4.1 MAMMALIAN EXPRESSION SYSTEMS 453
5.4.2 MICROBIAL EXPRESSION SYSTEMS 456
5.4.3 OTHERS (INSECT AND PLANT CELL) 457
5.5 CELL LINE DEVELOPMENT SERVICES, BASED ON CELL LINE TYPE 459
5.5.1 CHO 462
5.5.2 MURINE/MOUSE MYELOMA (NS0, SP2/0) 465
5.5.3 BABY HAMSTER KIDNEY (BHK) CELLS 466
5.5.4 HUMAN EMBRYONIC KIDNEY (HEK) CELLS 466
5.5.5 HUMAN EMBRYONIC RETINAL CELLS (PER.C6) 468
5.5.6 HYBRIDOMA 468
5.5.7 OTHERS (E.COLI, YEAST, INSECT CELL, HT-1080, HELA CELL LINE, CAP, HKB-11, HUH-7) 469
5.6 CELL LINE DEVELOPMENT SERVICES, BASED ON APPLICATIONS 474
5.6.1 RESEARCH 476
5.6.2 BIOPRODUCTION 480
5.6.3 DIAGNOSTICS 482
5.7 CELL BANKING SERVICES 497
5.8 CELL LINE CHARACTERIZATION SERVICES 499
5.9 MARKET SHARE ANALYSIS 502
5.10 KEY DEVELOPMENTS 507
5.10.1 AGREEMENT, COLLABORATION AND PARTNERSHIP 508
5.10.2 NEW TECHNOLOGY, PRODUCT AND SERVICE LAUNCH 511
5.10.3 OTHER DEVELOPMENTS 512
6 COMPANY PROFILES 516
6.1 ABBVIE INC. 516
6.1.1 OVERVIEW 516
6.1.2 FINANCIALS 518
6.1.3 SERVICE PORTFOLIO 520
6.1.4 KEY DEVELOPMENTS 522
6.1.5 SWOT ANALYSIS 522
6.2 AGC INC. 523
6.2.1 OVERVIEW 523
6.2.2 FINANCIALS 525
6.2.3 SERVICE PORTFOLIO 528
6.2.4 KEY DEVELOPMENTS 529
6.2.5 SWOT ANALYSIS 535
6.3 AVID BIOSERVICES, INC. 536
6.3.1 OVERVIEW 536
6.3.2 FINANCIALS 537
6.3.3 SERVICE PORTFOLIO 537
6.3.4 KEY DEVELOPMENTS 541
6.3.5 SWOT ANALYSIS 543
6.4 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 544
6.4.1 OVERVIEW 544
6.4.2 FINANCIALS 546
6.4.3 SERVICE PORTFOLIO 548
6.4.4 KEY DEVELOPMENTS 549
6.4.5 SWOT ANALYSIS 549
6.5 CATALENT INC. 550
6.5.1 OVERVIEW 550
6.5.2 FINANCIALS 552
6.5.3 SERVICE PORTFOLIO 554
6.5.4 KEY DEVELOPMENTS 555
6.5.5 SWOT ANALYSIS 563
6.6 CHARLES RIVER LABORATORIES 564
6.6.1 OVERVIEW 564
6.6.2 FINANCIALS 566
6.6.3 SERVICE PORTFOLIO 568
6.6.4 KEY DEVELOPMENTS 569
6.6.5 SWOT ANALYSIS 572
6.7 CURIA 573
6.7.1 OVERVIEW 573
6.7.2 FINANCIALS 573
6.7.3 SERVICE PORTFOLIO 573
6.7.4 KEY DEVELOPMENTS 576
6.7.5 SWOT ANALYSIS 578
6.8 EMERGENT BIOSOLUTIONS INC. 579
6.8.1 OVERVIEW 579
6.8.2 FINANCIALS 580
6.8.3 SERVICE PORTFOLIO 580
6.8.4 KEY DEVELOPMENTS 582
6.8.5 SWOT ANALYSIS 583
6.9 EUROFINS SCIENTIFIC S.E. 584
6.9.1 OVERVIEW 584
6.9.2 FINANCIALS 586
6.9.3 SERVICE PORTFOLIO 587
6.9.4 KEY DEVELOPMENTS 588
6.9.5 SWOT ANALYSIS 589
6.10 FUJIFILM HOLDINGS CORPORATION (FUJIFILM DIOSYNTH BIOTECHNOL0GIES) 590
6.10.1 OVERVIEW 590
6.10.2 FINANCIALS 592
6.10.3 SERVICE PORTFOLIO 594
6.10.4 KEY DEVELOPMENTS 594
6.10.5 SWOT ANALYSIS 598
6.11 GENSCRIPT BIOTECH CORPORATION 599
6.11.1 OVERVIEW 599
6.11.2 FINANCIALS 601
6.11.3 SERVICE PORTFOLIO 603
6.11.4 KEY DEVELOPMENTS 604
6.11.5 SWOT ANALYSIS 608
6.12 JSR CORPORATION 609
6.12.1 OVERVIEW 609
6.12.2 FINANCIALS 611
6.12.3 SERVICE PORTFOLIO 612
6.12.4 KEY DEVELOPMENTS 614
6.12.5 SWOT ANALYSIS 616
6.13 LABORATORY CORP OF AMERICA HOLDINGS 617
6.13.1 OVERVIEW 617
6.13.2 FINANCIALS 619
6.13.3 SERVICE PORTFOLIO 620
6.13.4 KEY DEVELOPMENTS 621
6.13.5 SWOT ANALYSIS 622
6.14 LONZA GROUP LTD. 623
6.14.1 OVERVIEW 623
6.14.2 FINANCIALS 625
6.14.3 SERVICE PORTFOLIO 627
6.14.4 KEY DEVELOPMENTS 629
6.14.5 SWOT ANALYSIS 638
6.15 MERCK KGA 639
6.15.1 OVERVIEW 639
6.15.2 FINANCIALS 641
6.15.3 PRODUCT PORTFOLIO 643
6.15.4 KEY DEVELOPMENTS 644
6.15.5 SWOT ANALYSIS 646
6.16 NATIONAL RESILIENCE, INC. 647
6.16.1 OVERVIEW 647
6.16.2 FINANCIALS 647
6.16.3 SERVICE PORTFOLIO 647
6.16.4 KEY DEVELOPMENTS 649
6.16.5 SWOT ANALYSIS 651
6.17 RENTSCHLER BIOPHARMA SE 652
6.17.1 OVERVIEW 652
6.17.2 FINANCIALS 652
6.17.3 SERVICE PORTFOLIO 653
6.17.4 KEY DEVELOPMENTS 654
6.17.5 SWOT ANALYSIS 657
6.18 SAMSUNG BIOLOGICS CO. LTD. 658
6.18.1 OVERVIEW 658
6.18.2 FINANCIALS 659
6.18.3 SERVICE PORTFOLIO 660
6.18.4 KEY DEVELOPMENTS 661
6.18.5 SWOT ANALYSIS 666
6.19 THERMO FISHER SCIENTIFIC INC. 667
6.19.1 OVERVIEW 667
6.19.2 FINANCIALS 669
6.19.3 SERVICE PORTFOLIO 671
6.19.4 KEY DEVELOPMENTS 672
6.19.5 SWOT ANALYSIS 676
6.20 WUXI APPTEC CO., LTD. 677
6.20.1 OVERVIEW 677
6.20.2 FINANCIALS 679
6.20.3 SERVICE PORTFOLIO 681
6.20.4 KEY DEVELOPMENTS 682
6.20.5 SWOT ANALYSIS 685
6.21 WUXI BIOLOGICS (CAYMAN) INC. 686
6.21.1 OVERVIEW 686
6.21.2 FINANCIALS 688
6.21.3 SERVICE PORTFOLIO 690
6.21.4 KEY DEVELOPMENTS 697
6.21.5 SWOT ANALYSIS 705
Related Report
